Table V.
Association of BglII and NdeI genotypes with clinical and biochemical characteristics in patients with DM2.
| A, BglII (risk allele, A; no-risk allele, G) | ||||
|---|---|---|---|---|
| Frequency of AA/AG/GG genotypes, n (%) | ||||
| Variable | DR patients | No-DR patients | P-valuec | OR (95% CI) |
| Cataract | 0 (0.0)/44 (65.7)/23 (34.3) | 0 (0)/81 (73.6)/29 (26.4) | 0.261 | 0.68 (0.35–1.32) |
| Duration of DM2 (≥15 years)a | 0 (0.0)/58 (72.5)/22 (27.5) | 0 (0)/76 (80.8)/18 (19.1) | 0.192 | 0.62 (0.31–1.27) |
| Dyslipidemiaa | 0 (0.0)/56 (77.8)/16 (22.2) | 0 (0.0)/69 (65.7)/36 (34.3) | 0.084 | 1.83 (0.92–3.63) |
| Cardiovascular diseasea | 0 (0.0)/52 (80.0)/13 (20.0) | 0 (0.0)/73 (65.2)/39 (34.8) | 0.037 | 2.14 (1.04–4.40) |
| Hypertensiona | 0 (0.0)/75 (72.8)/28 (27.2) | 0 (0.0)/64 (73.6)/10 (26.4) | 0.029 | 2.39 (1.08–5.29) |
| DM2a | 0 (0.0)/95 (73.1)/35 (26.9) | 0 (0.0)/30 (63.8)/17 (36.2) | 0.234 | 1.54 (0.76–3.13) |
| B, NdeI (risk allele, T; no-risk allele, C) | ||||
| Frequency of TT/TC/CC genotypes, n (%) | ||||
| Variable | DR patients | No-DR patients | P-valuec | OR (95% CI) |
| Cataract | 0 (0.0)/62 (92.5)/5 (7.5) | 0 (0.0)/106 (96.4)/4 (3.6) | 0.262 | 0.47 (0.12–1.81) |
| Duration of DM2 (≥15 years)b | 0 (0.0)/74 (92.5)/6 (7.5) | 0 (0.0)/89 (94.7)/5 (5.3) | 0.560 | 0.69 (0.20–2.31) |
| Dyslipidemiaa | 0 (0.0)/69 (95.8)/3 (4.2) | 0 (0.0)/99 (94.3)/6 (5.7) | 0.646 | 1.39 (0.34–5.76) |
| Cardiovascular diseasea | 0 (0.0)/62 (95.4)/3 (4.6) | 0 (0.0)/106 (94.6)/6 (5.4) | 0.829 | 1.17 (0.28–4.84) |
| Hypertensiona | 0 (0.0)/97 (94.1)/6 (5.8) | 0 (0.0)/71 (95.9)/3 (4.0) | 0.596 | 0.68 (0.17–2.82) |
| DM2a | 0 (0.0)/124 (95.4)/6 (4.6) | 0 (0.0)/44 (93.6)/3 (6.4) | 0.637 | 1.41 (0.34–5.88) |
a
Family history data
b
missing data
c
correlation/trend P-value. DM2, type 2 diabetes mellitus; OR, odds ratio; CI, confidence interval.